Management of acromegaly in Latin America: Expert panel recommendations

Pituitary

Volumn 13, Issue 2, 2010, Pages 168-175

  Barkan, Ariel ^a   Bronstein, Marcello D ^b   Bruno, Oscar D ^c   Cob, Alejandro ^d   Espinosa de los Monteros, Ana Laura ^e   Gadelha, Monica R ^f   Garavito, Gloria ^g   Guitelman, Mirtha ^h   Mangupli, Ruth ⁱ   Mercado, Moisés ^e   Portocarrero, Lesly ^j   Sheppard, Michael ^k  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^d HOSPITAL SAN JUAN DE DIOS   (Costa Rica)

^e HOSPITAL DE ESPECIALIDADES   (Mexico)

^f FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^g Instituto Nacional de Cancerología   (Colombia)

^h HOSPITAL DURAND   (Argentina)

ⁱ HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^j NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

Acromegaly; Growth hormone; Insulin like growth factor 1; Latin America; Octreotide; Radiotherapy; Somatostatin receptors; Surgery

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ACROMEGALY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC PROCEDURE; DISEASE CONTROL; DOSE RESPONSE; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS ADENOMA; LABORATORY TEST; ORAL GLUCOSE TOLERANCE TEST; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SOUTH AND CENTRAL AMERICA; VISUAL FIELD DEFECT; METABOLISM;

ACROMEGALY; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LATIN AMERICA; OCTREOTIDE; RECEPTORS, SOMATOSTATIN;

EID: 77955907906     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-009-0206-y     Document Type: Review

References (72)

1. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
2. Freda PU (2003) Pitfalls in the biochemical assessment of acromegaly. Pituitary 6:135-140
3. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558-2573
4. Strasburger CJ, Bidlingmaier M (2005) How robust are laboratory measures of growth hormone status? Horm Res 64(Suppl 2):1-5
5. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 67:65-70
6. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL (2004) Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89:2271-2274
7. Brabant G (2003) Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol 148(Suppl 2):S15-S20
8. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN (2003) Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 6:175-180
9. Dimaraki EV, Jaffe CA, Mott-Friberg R, Chandler WF, Barkan AL (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537-3542
10. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152:379-387
11. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER (2005) Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) 147:243-251
12. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM (1999) Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon. QJM 92:741-745
13. Shimon I, Cohen ZR, Ram Z, Hadani M (2001) Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 48:1239-1243
14. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
15. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
16. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66:859-868
17. Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, Lombardi G, Pivonello R, Ferone D (2009) Significant tumour shrinkage after 12 months of Lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 71:237-245
18. Bevan JS (2005) The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
19. Cook D (2009) Octreotide long-acting repeatable in acromegaly: achieving optimal control. The Endocrinologist 19:142-147
20. Ayuk J, Stewart SE, Stewart PM, Sheppard MC (2002) Longterm safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 87:4142-4146
21. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397-1403
22. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R (2006) Partial surgical removal of GH-secreting pituitary tumors enhances the response to somatostatin analogues in acromegaly. J Clin Endocrinol Metab 91:85-92
23. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD (2007) Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 67:310-315
24. Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2007) Treatment of acromegaly: is there still a place for radiotherapy? Pituitary 10:53-59
25. Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G (2006) First-line octreotide-LAR therapy induces tumor shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 64:342-351
26. Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2005) Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63: 168-175
27. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC (1995) Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 80:3267-3272
28. Mangupli R, Lisette A, Ivett C, Paul C, de los Rios V, Luis CJ (2003) Improvement of acromegaly after octreotide LAR treatment. Pituitary 6:29-34
29. Taboada GF, Donangelo I, Guimaraes RF, Silva MO, Fontes R, Gadelha MR (2005) Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR. Arq Bras Endocrinol Metabol 49:390-395
30. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, Jervell J (1995) Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 80:3601-3607
31. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB (2000) Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 53:719-724
32. Turner HE, Thornton-Jones VA, Wass JA (2004) Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 61:224-231
33. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2007) Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157:579-587
34. Attanasio R, Lanzi R, Losa M, Valentini F, Grimaldi F, De ME, Davi MV, Battista C, Castello R, Cremonini N, Razzore P, Rosato F, Montini M, Cozzi R (2008) Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 14:846-855
35. Yetkin DO, Boysan SN, Tiryakioglu O, Yalin AS, Kadioglu P (2007) Forty-month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide. Endocr J 54:459-464
36. Lancranjan I, Atkinson AB (1999) Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1:105-114
37. Biermasz NR, van den Oever NC, Frolich M, Arias AM, Smit JW, Romijn JA, Roelfsema F (2003) Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf) 58:288-295
38. Lucas T, Astorga R, The Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly (2006) Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 65:320-326
39. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-1617
40. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081-4086
41. Ayuk J, Sheppard MC (2007) Does acromegaly enhance mortality? Rev Endocr Metab Disord 9:33-39
42. Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, Ambrosio MR, Pivonello R, Lombardi G, Angeli A, degli Uberti EC (2008) GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol (Oxf) 69:613-620
43. Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90:1972-1978
44. Brooke AM, Drake WM (2007) Serum IGF-I levels in the diagnosis and monitoring of acromegaly. Pituitary 10:173-179
45. Bronstein MD (2006) Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res 35:129-134
46. Jackson SN, Fowler J, Howlett TA (1997) Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf) 46:745-749
47. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378
48. Lorcy Y, Dejager S, Chanson P (2000) Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary 3:193-197
49. Ronchi CL, Rizzo E, Lania AG, Pivonello R, Grottoli S, Colao A, Ghigo E, Spada A, Arosio M, Beck-Peccoz P (2008) Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 158:19-25
50. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-157
51. Cozzi R, Attanasio R, Lodrini S, Lasio G (2004) Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61:209-215
52. Gatta B, Hau DH, Catargi B, Roger P, Tabarin A (2005) Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf) 63:477-478
53. Selvarajah D, Webster J, Ross R, Newell-Price J (2005) Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 152:569-574
54. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38
55. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46
56. Ayuk J, Sheppard MC (2004) The role of growth hormonereceptor antagonism in relation to acromegaly. Expert Opin Pharmacother 5:2279-2285
57. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
58. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
59. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S (2000) Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85:2958-2961
60. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646
61. Schmid HA (2008) Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69-74
62. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P (2001) Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 86:140-145
63. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD (2005) Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 153:135-141
64. Growth Hormone Research Society, Pituitary Society (2004) Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 89:3099-3102
65. Espinosa-de-los-Monteros A, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, Mendoza V, Hernandez I, Molina M, Mercado M (2006) Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol (Oxf) 64:245-249
66. Freda PU, Post KD, Powell JS, Wardlaw SL (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 83:3808-3816
67. Biermasz NR, van Dulken H, Roelfsema F (2000) Ten-year follow- up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 85:4596-4602
68. Swearingen B, Biller BM, Barker FG, Katznelson L, Grinspoon S, Klibanski A, Zervas NT (1999) Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 130:821-824
69. Zirkzee EJ, Corssmit EP, Biermasz NR, Brouwer PA, Wiggers- De Bruine FT, Kroft LJ, Van Buchem MA, Roelfsema F, Pereira AM, Smit JW, Romijn JA (2004) Pituitary magnetic resonance imaging is not required in the postoperative follow-up of acromegalic patients with long-term biochemical cure after transsphenoidal surgery. J Clin Endocrinol Metab 89:4320-4324
70. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM (1997) Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:3187-3191
71. Barkan AL (2003) Radiotherapy in acromegaly: the argument against. Clin Endocrinol (Oxf) 58:132-135
72. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA (2006) Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91:1239-1245